Barbell Medicine Podcast cover image

Episode #231: BMI Controversy and New Drug Breakthroughs

Barbell Medicine Podcast

CHAPTER

Riptatritide: A New Drug for Obesity

The new drug, we think it's called Riptatritide or something like that. It is a glucagon, GIP, GLP1, triple agonist. There are three different sort of molecular targets for this drug formulation. Austin, you're going to take us through this phase two clinical trial that just got published. And so at the highest dose among the people who got up to the 12 milligram dose the average weight loss at 48 weeks was 24%.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner